Summary:
Click image to enlarge
Galderma is conducting a study of an investigational drug called nemolizumab for the treatment of Atopic Dermatitis/Eczema. The goal of the study is to evaluate the effect of the study drug on the way other drugs move throughout the body.
Qualified Participants Must:
• Be 18 years of age or older
•
Have been diagnosed Atopic Dermatitis/Eczema for at least 2 years
•
Have Atopic Dermatitis that covers 10% or more of their body
•
Be willing to stay overnight at the clinic for this study*Additional criteria may apply to participate. A study coordinator will be able to discuss your eligibility with you.
Qualified Participants May Receive:
Participants who qualify will receive the investigational drug, as well as study-related medical exams and laboratory tests, at no cost. Eligible participants will also receive compensation for time spent at the clinic, up to $2800, as well as meals during clinic stays.